Company profile: Akston Biosciences
1.1 - Company Overview
Company description
- Provider of novel biologics developed and manufactured via a fusion protein platform, offering veterinary therapies: once-weekly insulin for diabetic dogs and cats; a FcRn-recycled GLP-1 weekly therapy for cats addressing diabetes and obesity; canine and feline oncology treatments via growth factor receptor downregulation; and a canine therapeutic vaccine targeting NGF for chronic pain.
Products and services
- AKS-559c: An FcRn-recycled GLP-1, once-a-week therapy for cats, targeting diabetes and obesity through FcRn recycled GLP-1 with weekly dosing
- AKS-321d: A fusion-protein biologic, once-a-week insulin therapy for dogs with diabetes, engineered to replace twice-a-day treatments with weekly dosing
- AKS-425c: A fusion-protein biologic, once-a-week insulin therapy for cats with diabetes, architected as an alternative to twice-daily insulin treatments with weekly dosing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Akston Biosciences
Perceive Bio
HQ: United States
Website
- Description: Provider of novel ophthalmology technologies and therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perceive Bio company profile →
Semma Therapeutics
HQ: United States
Website
- Description: Provider of transformative therapies for Type 1 diabetes, leveraging an exclusively licensed breakthrough method from Professor Douglas Melton's lab to generate billions of functional, insulin-producing beta cells in the laboratory.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semma Therapeutics company profile →
Calibrium
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development, focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calibrium company profile →
Intuity Medical
HQ: United States
Website
- Description: Provider of blood glucose monitoring systems for diabetes management, featuring the POGO Automatic Monitor that automatically lances, collects blood, and provides results with a single press using 10-test cartridges that integrate lancets and test strips, and the Patterns app to sync, track, visualize trends, share readings, send emergency notifications, and integrate with other health apps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intuity Medical company profile →
Kaleido
HQ: The Netherlands
Website
- Description: Provider of wearable insulin pump solutions for diabetes management, including the Kaleido insulin pump delivering continuous fast-acting insulin over 24 hours with hourly adjustments, connecting via a tube and infusion set and wearable up to three days; the Kaleido with Diabeloop’s DBLG1 Hybrid Closed Loop using Dexcom G6 and a handheld device to auto-adjust dosing; and a starter kit with two reusable pumps, a handset, training and support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kaleido company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Akston Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Akston Biosciences
2.2 - Growth funds investing in similar companies to Akston Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Akston Biosciences
4.2 - Public trading comparable groups for Akston Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →